All canine diagnoses

Your dog was diagnosed with Oral Fibrosarcoma. Third most common oral malignancy in dogs. Critical diagnostic trap: oral fibrosarcoma in large breeds (especially Golden Retrievers, 54% of cases) appears histologically low-grade but behaves aggressively (high local recurrence, metastatic potential). Predominantly maxillary location (72%). Compare 2 treatment options for dogs including Mandibulectomy / Maxillectomy, Surgery + Adjuvant Hypofractionated Radiation — with survival times, costs, and what to expect during treatment.

🐕

Oral Fibrosarcoma

BreedsGolden RetrieverLarge breed dogs generally
canine

Mesenchymal

About This Cancer

Oral fibrosarcoma is the third most common malignant tumour of the mouth in dogs, arising from fibrous connective tissue cells (fibroblasts). A critical feature of this cancer in large breed dogs, particularly Golden Retrievers, is that it presents a diagnostic trap: under the microscope the tumour cells may appear relatively benign and well-differentiated (low-grade histology), yet the tumour actually behaves very aggressively with high rates of local invasion into bone and a significant risk of distant spread. This disconnect between microscopic appearance and clinical behaviour is well-recognised in veterinary oncology and means that pathology reports can be misleadingly reassuring. The tumour most commonly develops in the upper jaw (maxilla) and is treated with aggressive surgical excision — the adequacy of surgical margins is the most important factor in determining outcome.

WHO Clinical Staging for Canine Oral Tumours (TNM)

Standard TNM staging system for canine oral tumours. Applicable to oral fibrosarcoma, melanoma, SCC, and other oral malignancies.

Stage T1Tumour <2 cm maximum diameter
Stage T2Tumour 2-4 cm maximum diameter
Stage T3Tumour >4 cm maximum diameter
Stage N0No regional lymph node metastasis
Stage N1Ipsilateral movable lymph node involvement
Stage N2Bilateral or contralateral movable lymph node involvement
Stage N3Fixed lymph node involvement
Stage M0No distant metastasis
Stage M1Distant metastasis
Prognostic Factors(2)
Location (maxilla vs mandible)Mandibulectomy: MST 10–12 months, 10% local recurrence. Maxillectomy: MST 11–12 months, 33% local recurrence. Mandibulectomy has better local control.(Frazier et al., 2012 (PMID 22236095))
The histologic-biologic discordancePathologists may undergrade oral FSA in large breeds. An 'aggressive treatment approach is always warranted' regardless of apparent histologic grade.(Ciekot et al., 1994)
Minimum Workup(5 steps)
1Incisional biopsy with histopathology
2CT of skull (extent of bone invasion, surgical planning)
3Three-view thoracic radiographs
4Regional lymph node assessment (mandibular, retropharyngeal)
5Complete blood count and biochemistry

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Mandibulectomy / Maxillectomy
~18 mo (7–34)
Surgery + Adjuvant Hypofractionated Radiation
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.